World's Best Scientists 2026 revealed!
Kevan C. Herold

Kevan C. Herold

D-Index & Metrics

Immunology

D-Index
99
Citations
36621
World Ranking
749
National Ranking
425

Medicine

D-Index
99
Citations
37046
World Ranking
8578
National Ranking
4419

Overview

Kevan C. Herold is affiliated with Yale University in the United States and has contributed extensively to academic research in medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields, including genetics, endocrinology, diabetes and metabolism, surgery, immunology, and oncology.

Their research interests focus primarily on diabetes and associated disorders, diabetes management and research, pancreatic function and diabetes, immune cell function and interaction, cancer immunotherapy and biomarkers, diabetes treatment and management, and COVID-19 clinical research studies.

Herold has published numerous papers in several reputed scientific venues, with frequent contributions to journals such as Diabetes, Diabetes Care, The Journal of Immunology, Journal for ImmunoTherapy of Cancer, and bioRxiv (Cold Spring Harbor Laboratory).

Notable recent papers include:

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients (2020, Science Translational Medicine)
  • Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals (2021, Science Translational Medicine)
  • Quantifying the effect of experimental perturbations at single-cell resolution (2021, Nature Biotechnology)
  • The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes (2021, JCI Insight)
  • Immunotherapy: Building a bridge to a cure for type 1 diabetes (2021, Science)

Frequent co-authors collaborating with Herold include:

  • Jay M. Sosenko
  • María J. Redondo
  • Emily K. Sims
  • Heba M. Ismail
  • Stephen E. Gitelman

Herold's body of work demonstrates a strong focus on diabetes-related research, evidenced by a high number of publications specifically in diabetes-focused journals. Their contributions to immunology and oncology also integrate with their medical research pursuits.

Best Publications

  • Genetics, pathogenesis and clinical interventions in type 1 diabetes

    Jeffrey A. Bluestone;Kevan Herold;George Eisenbarth

  • Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

    Kevan C. Herold;William Hagopian;Julie A. Auger;Ena Poumian-Ruiz

  • Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

    Richard A. Insel;Jessica L. Dunne;Mark A. Atkinson;Jane L. Chiang

  • Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

    Jeffrey A. Bluestone;Jane H. Buckner;Mark Fitch;Stephen E. Gitelman

  • Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

    Ravichandran Ramasamy;Susan J. Vannucci;Shirley Shi Du Yan;Kevan Herold

  • An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Kevan C. Herold;Brian N. Bundy;S. Alice Long;Jeffrey A. Bluestone

  • Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

    Deborah J. Lenschow;Stephen C. Ho;I Husain Sattar;Lesley Rhee

  • A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

    Kevan C. Herold;Stephen E. Gitelman;Umesh Masharani;William Hagopian

  • Reprogramming human T cell function and specificity with non-viral genome targeting

    Theodore L. Roth;Cristina Puig-Saus;Ruby Yu;Ruby Yu;Eric Shifrut;Eric Shifrut

  • Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation

    B Glaser;P Kesavan;M Heyman;E Davis

  • C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function: Report of an ADA Workshop, 21–22 October 2001

    Jerry P. Palmer;G. Alexander Fleming;Carla J. Greenbaum;Kevan C. Herold

  • Control of TH17 cells occurs in the small intestine.

    Enric Esplugues;Enric Esplugues;Enric Esplugues;Samuel Huber;Samuel Huber;Nicola Gagliani;Anja E. Hauser

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

    Kevan C. Herold;Stephen E. Gitelman;Mario R. Ehlers;Peter A. Gottlieb

  • CD28/B7 Regulation of Th1 and Th2 Subsets in the Development of Autoimmune Diabetes

    Deborah J. Lenschow;Kevan C. Herold;Lesley Rhee;Bina Patel

  • TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

  • Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    Diane K Wherrett;Brian Bundy;Dorothy J Becker;Linda A DiMeglio

  • Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

    Antoinette Moran;Brian Bundy;Dorothy J. Becker;Linda A. DiMeglio

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.

    Carl A. Pierce;Paula Preston-Hurlburt;Yile Dai;Clare Burn Aschner

  • TCR stimulation with modified anti-CD3 mAb expands CD8 + T cell population

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

Frequent Co-Authors

Jeffrey A. Bluestone
Jeffrey A. Bluestone University of California, San Francisco
Carla J. Greenbaum
Carla J. Greenbaum Virginia Mason Medical Center
Jerry P. Palmer
Jerry P. Palmer University of Washington
Jay S. Skyler
Jay S. Skyler University of Miami
Mark A. Atkinson
Mark A. Atkinson University of Florida
Jeffrey P. Krischer
Jeffrey P. Krischer University of South Florida
Desmond A. Schatz
Desmond A. Schatz University of Florida
Ann Marie Schmidt
Ann Marie Schmidt New York University
Linda A. DiMeglio
Linda A. DiMeglio Indiana University
Raphael Clynes
Raphael Clynes Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare disciplines, particularly nursing specialties focused on patient immune response and related conditions. Aspiring professionals can explore accelerated paths, such as an accelerated np program, which offers a fast-tracked approach to becoming a nurse practitioner with specialized knowledge valuable in immunology-related fields.

For those already in nursing, transitioning to acute care is a viable option with programs like an fnp to acnp bridge program online, equipping nurse practitioners with critical skills for managing complex immune system disorders. This flexibility allows for career growth in both clinical and research settings.

Financial considerations are key when selecting education pathways. Some of the cheapest online pmhnp certificate programs offer an affordable entry point, enabling learners to minimize debt while gaining credentials relevant to immunology-related mental health conditions.

Career prospects also depend on specialization. Graduates often target high-demand, well-compensated roles, reminiscent of those found in the highest paid dnp specialties, where expertise in immunology can enhance earning potential and job satisfaction.

Best Scientists Citing Kevan C. Herold

Trending Scientists